How a specific insulin peptide can help prevent immune attacks on insulin-producing cells in diabetes.
Induction of tolerance to a Hybrid Insulin Peptide and the impact on autoreactive T cell fate and function in autoimmune diabetic islet transplant
['FUNDING_FELLOWSHIP'] · UNIVERSITY OF COLORADO DENVER · NIH-10995525
This study is looking at a new way to help people with Type 1 Diabetes by using a special insulin peptide to teach the immune system to stop attacking the cells that make insulin, with hopes of improving treatments and possibly reversing the condition.
Quick facts
| Phase | ['FUNDING_FELLOWSHIP'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF COLORADO DENVER (nih funded) |
| Locations | 1 site (Aurora, UNITED STATES) |
| Trial ID | NIH-10995525 on ClinicalTrials.gov |
What this research studies
This research investigates a novel approach to treating Type 1 Diabetes (T1D) by using a specific insulin peptide to induce tolerance in the immune system. The study focuses on how this peptide can suppress harmful T cells that attack insulin-producing beta cells in the pancreas. By using a mouse model, researchers will explore the mechanisms behind this tolerance and its effects on T cell behavior, aiming to improve the survival of islet transplants. The ultimate goal is to develop a therapy that could help manage or even reverse autoimmune diabetes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Type 1 Diabetes who may benefit from improved immune tolerance therapies.
Not a fit: Patients with Type 2 Diabetes or those whose diabetes is not autoimmune in nature may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that protect insulin-producing cells and improve outcomes for patients with Type 1 Diabetes.
How similar studies have performed: Previous studies have shown promise in using antigen-specific immunotherapy to induce tolerance in autoimmune conditions, suggesting potential success for this approach.
Where this research is happening
Aurora, UNITED STATES
- UNIVERSITY OF COLORADO DENVER — Aurora, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DILISIO, JAMES E — UNIVERSITY OF COLORADO DENVER
- Study coordinator: DILISIO, JAMES E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Autoimmune Diabetes, Autoimmune Diseases, Brittle Diabetes Mellitus